Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

NCT05889351 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasal Decolonization of Staphylococcus Aureus

Interventions

DRUG: Vehicle gel, 4 + 4 applications or 4 + 2 applications
DRUG: LTX-109 3% gel, 4 + 4 applications
DRUG: LTX-109 3% gel, 4 + 2 applications

Sponsor

Pharma Holdings AS

Collaborators

[object Object]